Essential hypertension
Conditions
Interventions
SEE-THRU BP is a 16-week, cross-over, prospective, randomized, open, blinded-endpoint (PROBE) study. After a screening phase for eligibility, baseline data are obtained. Then, patients are assigned to
Group 1) or atenolol (50mg, daily
Group 2) for 8 weeks. Group 1: Antihypertensive drugs other than telmisartan, if any at baseline, are continued and not changed throughout the study period. After 8 weeks, telmisartan is switched
Group 2) for 8 weeks. Group 2: Antihypertensive drugs other than atenolol, if any at baseline, are continued and not changed throughout the study period. After 8 weeks, atenolol is switched to t
Sponsors
Nagoya City University Graduate School of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with hypertension who have not been treated with antihypertensive drug
Exclusion criteria
Exclusion criteria: Exclusion criteria are: history of coronary heart disease, heart failure, or stroke; diabetes mellitus; metabolic syndrome; malignant neoplasm; active inflammatory disease; pregnant women
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary endpoint is the change in the plasma S1P concentration and endothelial function from baseline to 8 weeks after each treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary endpoints: (1) The change in lipid profiles (total cholesterol, HDL-cholesterol, LDL-cholesterol, triglycerides) from baseline to 8 weeks after each treatment. (2) The change in fasting plasma glucose, C-reactive protein, serotonin, malondialdehyde-modified low-density lipoproteitn (MDA-LDL) from baseline to 8 weeks after each treatment. (3) The change in urine albumin excretion from baseline to 8 weeks after each treatment. (4) The change in brachial-ankle pulse wave velocity from baseline to 8 weeks after each treatment. (5) The change in the number of progenitor cell (CD34+ cell) from baseline to 8 weeks after each treatment. (6) The change in the number of endothelial progenitor cells (positive for DiI-acLDLuptake and FITC-lectin binding staining) from baseline to 8 weeks after each treatment. (7) The change in brachial blood pressure, estimated central aortic pressure, and heart rate from baseline to 8 weeks after each treatment. (8) The change in expression of microRNA associated with endothelial function from baseline to 8 weeks after each treatment. | — |
Countries
Japan
Outcome results
None listed